Needham raised the firm’s price target on Cogent Biosciences to $18 from $15 and keeps a Buy rating on the shares. The analyst cites its view of a higher peak market share and probability of success for bezuclastinib in ISM, indolent systemic mastocytosis, following data from SUMMIT Part 1b at AAAAI.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on COGT:
- Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
- Cogent Biosciences Launches $225M Private Stock Sale
- Cogent Biosciences announces oversubscribed $225M private placement
- Cogent Biosciences sells 17M shares at $7.50 in private placement
- Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
